about
Two critical hits for promyelocytic leukemiaThe role of micro-ribonucleic acids in normal hematopoiesis and leukemic T-lymphogenesisThe recognition of N-glycans by the lectin ArtinM mediates cell death of a human myeloid leukemia cell lineIdentification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway.Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects.The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylatedDifferentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.Epidemiology and treatment of acute promyelocytic leukemia in latin americaActive Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancerHalofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.Granulocyte colony-stimulating factor and leukemogenesis.Intracranial Castleman's disease presenting as hypopituitarism.In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.Role of promyelocytic leukemia (PML) protein in tumor suppressionThe results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countriesIncreased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America.Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells.(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.Interaction of 10-(octyloxy) decyl-2-(trimethylammonium) ethyl phosphate with mimetic membranes and cytotoxic effect on leukemic cells.Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice.Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita.PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia.Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia.All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.Biological X-ray irradiator characterization for use with small animals and cells.The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia.
P50
Q28139515-8940985E-E752-406C-BE18-8C08F2ED7CD1Q28645911-84EBAB2F-2DEF-448A-A3F3-159BB952755CQ28742329-2863DA88-211A-4FBC-81BF-FF687C3CC979Q33560404-604F5DE4-D675-4803-9A0B-8584CD34DF2CQ34067009-56027A58-60DF-4B46-ADBE-E0153171FE95Q34600410-63990D75-A465-4494-864D-B9C3C787206CQ34657243-718D2AC3-B71D-4E8D-A396-AE5B8818FF7FQ34750625-7E8A60A2-7B06-48D1-958C-D1AA435FBE5DQ35560264-C1D4F7DF-3312-4C69-9186-A06AA19D6FCDQ35560268-E034FCEC-2136-4FB8-A420-CDF873BEFC90Q35587470-73565D72-57A5-4DA6-A321-9B9DB366DAB1Q35800540-ED5C74F9-B9CF-413A-9D58-3633C65CA137Q35820983-4718B255-FEC5-4ABB-A1CA-2508A1E216D7Q35858450-6E80D43F-E79A-42A5-8793-DFFDAB9EC32FQ36228502-4E2AF9DC-F018-4429-802D-FBB6ABCC9537Q36262865-EDDDCFAA-9165-4CE7-888A-E49642001607Q36376155-9CCEC36A-6F87-4335-A687-91A61BA9CD91Q36753253-5A5B6C3D-D25B-4370-91CA-E3AAB8EEDB72Q36797960-4A92710B-6D07-4CF8-A8AB-0ED963421C42Q37683361-766A9864-89DC-46A1-BCDF-6F4DD9950E76Q37702740-8AB0CB8B-F80A-4931-B8D6-66C0138B695BQ37807000-95B9D64D-CF54-4531-9F6D-3E8A6004D6DBQ38895219-63D72339-AF1B-4D5A-AF85-0FA1CB03B9C7Q38916984-452CFF10-0271-4279-B02C-FB9EA79D5C94Q39273308-75B751CC-C7C4-4A03-9F43-300816583A18Q39280119-BBFE0DBD-931D-4273-B832-1F7B98A3E2F6Q39444447-07E20C01-4794-4C50-938D-E493774EC82DQ39484168-91E0C8FE-A03F-41AF-80CE-96FF7048492FQ39701932-ED3F0AB7-56BC-465A-A05A-1C5AD21C661FQ40052805-754B1FA1-B9CA-49BF-A3A0-6850677BEDE1Q40083143-5B2D2510-2A4D-4AE9-8A00-FA5602557ED2Q40280985-E552F84A-6D07-4276-9B7E-BFAEBDAA1C51Q40291007-AE54E17B-F958-49F1-9D61-2937305BD479Q40441691-8829270F-1223-497D-B04C-98AAEAC7A01CQ40890351-BB313E00-F9A5-4CE9-B8E6-4184FDF7293BQ41500318-B976B462-CC45-473E-924B-53307394BDAEQ41737559-C7D4A83E-8769-429F-B23E-11951AFD5090Q42047446-19330CB4-31FC-4518-B1FD-7B9ADC48B014Q42111120-4E3CA4F1-4B79-448D-8C72-14F0AF81BC41Q42137618-8130C186-4B84-4F67-AA4F-EBC88C160B7A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eduardo Magalhães Rego
@ast
Eduardo Magalhães Rego
@en
Eduardo Magalhães Rego
@es
Eduardo Magalhães Rego
@nl
Eduardo Magalhães Rego
@sl
type
label
Eduardo Magalhães Rego
@ast
Eduardo Magalhães Rego
@en
Eduardo Magalhães Rego
@es
Eduardo Magalhães Rego
@nl
Eduardo Magalhães Rego
@sl
prefLabel
Eduardo Magalhães Rego
@ast
Eduardo Magalhães Rego
@en
Eduardo Magalhães Rego
@es
Eduardo Magalhães Rego
@nl
Eduardo Magalhães Rego
@sl
P1053
A-1058-2012
P106
P21
P31
P3829
P496
0000-0003-1567-4086